ST Elevation Myocardial Infarction

CHELMSFORD, Mass.--( BUSINESS WIRE )--ZOLL ® , an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has been enrolled in the S uper S aturated oxygen C omprehensive O bservational RE gistry (SSCORE). The prospective study is designed to provide further evidence of the efficacy of SuperSaturated Oxygen (SSO 2 ) Therapy to reduce heart failure and mortality in patients suffering from left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks, the most serious type of heart attack. LAD STEMI heart attacks are often referred to as “widow makers” due to the high mortality rate associated with this condition. Additionally, SSCORE will collect data to substantiate the potential improvement in overall healthcare costs associated with prevention of heart failure versus a lifetime of palliative treatment strategies. The Minneapolis Heart Institute at Abbott Northwestern Hospital, a partner of Allina Health with multiple locations in Minneapolis, Minnesota, is one of the early adopters of the revolutionary SSO 2 Therapy, leading to their prominent position as first enroller in the study. “These patients with LAD occlusion are at significant risk. Opening the artery is the first step but using SSO 2 to further decrease infarct size is vital. This patient had an acute proximal LAD occlusion and I wanted to give him the best chance of preserving his heart function,” stated Dr. M. Nicolas Burke, Director of Cardiovascular Emergency Services at Abbott Northwestern, who treated the first patient enrolled in SSCORE nationwide. “Enrolling the first patient in the SSCORE study marks a significant milestone in advancing the use of SuperSaturated Oxygen Therapy to treat the most severe heart attacks," said Matt Rochner, General Manager of ZOLL TherOx. "SSO 2 Therapy has the potential to not only improve patient outcomes but also reduce the long-term costs of managing heart failure, a significant healthcare challenge. Our partnership with the Minneapolis Heart Institute and Allina Health allows us to advance this cutting-edge technology by collecting more evidence-based clinical and economic data, positioning SSO 2 Therapy to become the standard of care for LAD STEMI patients." Patients with LAD STEMI heart attacks have higher mortality rates than those with other types of heart attacks. SSO 2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce damage to cardiac muscle in heart attack patients after coronary angioplasty with stenting. 1 The extent of damaged cardiac muscle is a strong predictor of future outcomes like rehospitalization and the development of heart failure. 2 SSO 2 Therapy is indicated as an adjunct for patients who suffer LAD STEMI and are treated with traditional stenting within six hours of chest pain onset. The therapy delivers high levels of dissolved oxygen (7–10 times the amount normally found in the bloodstream) directly to the damaged heart muscle immediately after the coronary artery has been successfully opened via angioplasty and stenting. Multiple clinical trials have demonstrated the safety and efficacy of SSO 2 Therapy to reduce infarct size, a strong predictor of subsequent outcomes. 1, 3 -6 “The focus on reducing infarct size and improving microvascular function with SSO 2 in the cath lab versus palliation of disease is a logical strategy that has been long awaited in this field,” said Dr. Jay Traverse, Principal Investigator and Researcher at Allina’s Minneapolis Heart Institute Foundation, and an Interventional Cardiologist at Allina’s Minneapolis Heart Institute. “Persistently high readmission rates for these patients, who often develop heart failure following standard-of-care stenting of the LAD, have been an ongoing challenge for over two decades. SuperSaturated Oxygen Therapy has shown great promise to alleviate this problem, which improves the quality of life for the patient while relieving the financial burden on the healthcare system as a whole. We are excited to participate in this trial and look forward to seeing positive outcomes.” About ZOLL ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com . About Asahi Kasei The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com . Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/ . 1 Stone GW, et al. Circ Cardiovasc Intervent 2009;2:366-75. 2 Stone GW et al. J Am Coll Cardiol. 2016;67(14):1674–83. 3 O’Neill WW, et al. Jour of Am Coll Cardiol. 2007;50: 5:397-405. 4 David SW, et al. Catheter Cardiovasc Interv. 2018;1–9. 5 https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2020-ICD-10-PCS-Guidelines.pdf 6 Chen S, et al. Catheter Cardiovasc Interv. 2020; 1–7. Copyright © 2024 ZOLL Medical Corporation. All rights reserved. ZOLL and TherOx are registered trademarks of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.

ONTARIO, Calif.--( BUSINESS WIRE )--Prime Healthcare today announced its hospitals have been honored with Get With The Guidelines® (GWTG) Quality Achievement Awards from the American Heart Association for the treatment of heart failure and stroke. The American Heart Association recognized 23 Prime Healthcare hospitals with the Get With The Guidelines® - Heart Failure Award, highlighting the hospitals’ dedication to improving outcomes for heart failure patients by reducing readmissions and increasing the number of healthy days spent at home. Additionally, 29 Prime Healthcare hospitals received the Get With The Guidelines® - Stroke Award, recognizing commitment to providing the most appropriate treatment for stroke patients based on research-based guidelines. Moreover, four Prime Healthcare hospitals received the Coronary Artery Disease STEMI Receiving recognition for their rapid and research-based care for individuals experiencing a specific type of heart attack known as an ST elevation myocardial infarction (STEMI), which is considered more severe and dangerous than other types of heart attacks. “We are pleased to recognize the leaders and teams across Prime Healthcare hospitals for a strong commitment to caring for people with heart failure,” said Sabra Lewsey, MD, MPH, chair of the American Heart Association Heart Failure System of Care Advisory Group and Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. “Hospitals that participate in Get With The Guidelines often see better patient outcomes, fewer readmissions and lower mortality rates – a win for families, communities and health care systems.” The Get With The Guidelines quality achievement award is earned by hospitals that demonstrate a commitment to treating patients according to the most up-to-date guidelines outlined by the American Heart Association. This program leverages the expertise of the American Heart Association to ensure that patient care aligns with the latest research- and evidence-based guidelines, aiming to increase healthy days at home and reduce hospital readmissions for heart failure patients. “As a physician-founded and led organization, clinical quality and evidence-based care are at the core of our values,” said Sunny Bhatia, MD, Prime Healthcare President and Chief Medical Officer. “All Prime hospitals are dedicated to improving the quality of care for our patients with heart failure and stroke by implementing the Get With The Guidelines initiatives. The guidelines allow us to better track and measure our success in meeting evidenced-based clinical guidelines developed to improve outcomes for our patients. Thank you to our highly trained teams across the nation for achieving this recognition that saves lives and leads to healthier communities.” Many of the hospitals recognized also received the American Heart Association’s Target: Type 2 Diabetes Honor Roll™ award. This initiative aims to ensure that patients with Type 2 diabetes, who might be at higher risk for complications, receive the most up-to-date, evidence-based care when hospitalized due to heart disease or stroke. The following hospitals received the Stroke Award: Gold Plus: Centinela Hospital Medical Center , Inglewood, CA – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Honor Roll Dallas Regional Medical Center , Mesquite, TX – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Honor Roll Desert Valley Hospital , Victorville, CA – Gold Plus Target Type 2 Diabetes Honor Roll Encino Hospital Medical Center , Encino, CA – Gold Plus Target Type 2 Diabetes Honor Roll Garden City Hospital , Garden City, MI – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Honor Roll Garden Grove Hospital Medical Center , Garden Grove, CA – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Honor Roll Harlingen Medical Center , Harlingen, TX – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Plus Honor Roll Knapp Medical Center , Weslaco, TX – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Honor Roll Lake Huron Medical Center , Port Huron, MI – Gold Plus Target Type 2 Diabetes Honor Roll Landmark Medical Center , Woonsocket, RI – Gold Plus Target Type 2 Diabetes Honor Roll Lower Bucks Hospital , Bristol, PA – Gold Plus Target Type 2 Diabetes Honor Roll Mission Regional Medical Center , Mission, TX, – Gold Plus Target Type 2 Diabetes Honor Roll Paradise Valley Hospital , National City, CA – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Honor Roll Providence Medical Center , Kansas City, KS – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Honor Roll Riverview Regional Medical Center , Gadsden, AL – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Honor Roll Roxborough Memorial Hospital , Philadelphia, PA – Gold Plus Target Type 2 Diabetes Honor Roll Saint Clare’s Denville Hospital , Denville, NJ – Gold Plus Target Type 2 Diabetes Honor Roll Saint Mary’s Regional Medical Center , Reno, NV – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Honor Roll San Dimas Community Hospital , San Dimas, CA – Gold Plus Target Type 2 Diabetes Honor Roll Shasta Regional Medical Center , Redding, CA – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Honor Roll Sherman Oaks Hospital , Sherman Oaks, CA – Gold Plus Target Type 2 Diabetes Honor Roll Southern Regional Medical Center , Riverdale, GA – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Plus Honor Roll St. Francis Medical Center , Lynwood, CA – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Honor Roll St. Joseph Medical Center , Kansas City, MO – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Honor Roll St. Mary’s General Hospital , Passaic, NJ – Gold Plus Target Type 2 Diabetes Honor Roll St. Mary’s Medical Center , Blue Springs, MO – Gold Plus Target Type 2 Diabetes Honor Roll Target Stroke Elite Plus Honor Roll Suburban Community Hospital , East Norriton, PA – Gold Plus Target Type 2 Diabetes Honor Roll Silver Plus: Pampa Regional Medical Center , Pampa, TX – Silver Plus Target Type 2 Diabetes Honor Roll West Anaheim Medical Center , West Anaheim, CA – Silver Target Type 2 Diabetes Honor Roll The following hospitals received the Heart Failure Award: Gold Plus: Centinela Hospital Medical Center , Inglewood, CA – Target Type 2 Diabetes Honor Roll Chino Valley Medical Center , Chino, CA – Target Type 2 Diabetes Honor Roll Saint Clare’s Denville Hospital , Denville, NJ – Target Type 2 Diabetes Honor Roll Coshocton Regional Medical Center , Coshocton, OH – Target Type 2 Diabetes Honor Roll Desert Valley Hospital , Victorville, CA – Target Type 2 Diabetes Honor Roll Encino Hospital Medical Center , Encino, CA – Target Type 2 Diabetes Honor Roll Garden City Hospital , Garden City, MI – Target Type 2 Diabetes Honor Roll Garden Grove Hospital Medical Center , Garden Grove, CA – Target Type 2 Diabetes Honor Roll Huntington Beach Hospital , Huntington Beach, CA – Target Type 2 Diabetes Honor Roll La Palma Intercommunity Hospital , La Palma, CA – Target Type 2 Diabetes Honor Roll Montclair Hospital Medical Center , Montclair, CA – Target Type 2 Diabetes Honor Roll North Vista Hospital, North Las Vegas, NV – Target Type 2 Diabetes Honor Roll Paradise Valley Hospital , National City, CA – Target Type 2 Diabetes Honor Roll Saint Clare’s Health , Denville, NJ – Target Type 2 Diabetes Honor Roll Saint Michael’s Medical Center , Newark, NJ – Gold Plus Target Type 2 Diabetes Honor Roll San Dimas Community Hospital , San Dimas, CA – Target Type 2 Diabetes Honor Roll Shasta Regional Medical Center , Redding, CA – Target Type 2 Diabetes Honor Roll Sherman Oaks Hospital , Sherman Oaks, CA – Target Type 2 Diabetes Honor Roll Target HF Honor Roll St. Joseph Medical Center , Kansas City, MO – Target Type 2 Diabetes Honor Roll St. Mary’s Medical Center , Blue Springs, MO – Target Type 2 Diabetes Honor Roll Target HF Honor Roll Suburban Community Hospital , East Norriton, PA – Target Type 2 Diabetes Honor Roll West Anaheim Medical Center, West Anaheim, CA – Target Type 2 Diabetes Honor Roll Silver Plus: East Liverpool City Hospital , East Liverpool, OH – Silver Plus Target Type 2 Diabetes Honor Roll Saint Mary’s Regional Medical Center , Reno, NV – Silver Plus Target Type 2 Diabetes Honor Roll Target HF Honor Roll The following hospitals received the Coronary Artery Disease Award: Dallas Medical Center , Dallas, TX – Silver Receiving Target Type 2 Diabetes Honor Roll, NSTEMI Gold Saint Clare’s Health , Denville, NJ – Gold Receiving Plus Target Type 2 Diabetes Honor Roll St. Joseph Medical Center , Kansas City, MO – Gold Receiving Plus Target Type 2 Diabetes Honor Roll St. Mary’s Medical Center , Blue Springs, MO – Gold Receiving Target Type 2 Diabetes Honor Roll, NSTEMI Gold About Prime Healthcare and Prime Healthcare Foundation Prime Healthcare is an award-winning health system operating 44 hospitals and more than 300 outpatient locations in 14 states, providing over 2.2 million patient visits annually. It is one of the nation’s leading health systems, with nearly 45,000 employees and affiliated physicians dedicated to providing the highest quality healthcare. Fourteen of the Prime Healthcare hospitals are members of the Prime Healthcare Foundation, a not-for-profit public charity. Based in Ontario, California, Prime Healthcare is nationally recognized for award-winning quality care and has been named a Top 10 and Top 15 Health System by IBM Watson Health. To learn more, please visit www.primehealthcare.com . About Get With The Guidelines Get With The Guidelines ® is the American Heart Association/American Stroke Association’s hospital-based quality improvement program that provides hospitals with the latest research-based guidelines. Developed with the goal of saving lives and hastening recovery, Get With The Guidelines has touched the lives of more than 14 million patients since 2001. For more information, visit heart.org . Find us on: LinkedIn: linkedin.com/company/prime-healthcare/ Facebook: facebook.com/primehealthcare/ Instagram: instagram.com/prime_healthcare/

BAAR, Switzerland--( BUSINESS WIRE )-- CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital , CorFlow's initial VC investor and largest shareholder. Merieux Equity Partners , Laerdal Million Lives Fund , Wellington Partners , M&L Investments , Unorthodox Ventures , KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate . Concurrent with the financing, David Prim of Broadview Ventures, Barbara Castellano of Panakes Partners, Yoann Bonnamour of Merieux Equity Partners, and Rhiya Pau of Laerdal Million Lives Fund have joined the CorFlow Board of Directors. The Series B will fund the MOCA II ( M V O with C oFI TM System A ssessment II) pivotal study intended to gain US market clearance. The trial will run in the US and Europe and aims to validate CorFlow’s CoFl system to diagnose MVO in heart attack patients immediately following stent implantation. Additionally, it will fund an adaptive platform therapy study evaluating treatment effects of therapeutic agents delivered locally through the CoFl system on heart attack patients diagnosed with MVO. MVO affects more than half of all patients who suffer an acute heart attack and is an independent predictor for heart failure and mortality. Currently not routinely diagnosed MVO remains largely untreated, leading to poor patient outcomes, and contributing to high health care costs associated with cardiovascular disease. CorFlow’s CoFl system is being developed to provide timely, accurate and consistent detection of MVO while patients are still in the catheter laboratory (cath lab) immediately following the reopening of the larger epicardial arteries with a stent. Uniquely, the technology has been designed to also enable localized delivery of therapeutics to the microvasculature upon MVO diagnosis. CoFl also seamlessly integrates into standard workflows utilizing existing guide catheter and wire access. "We are thrilled to have closed on this significant round of financing, backed by a top-tier global syndicate of medical technology investors," commented Paul Mead, President and Chief Executive Officer of CorFlow. "Recent data from over 70 patients in our MOCA I first in human trial and from our extensive preclinical program support our collective confidence that we can improve outcomes in patients who suffer heart attacks, specifically those patients whose microvascular disease goes undiagnosed and untreated today. There is overwhelming evidence now that microvascular conditions are a significant root cause of adverse outcomes in heart attack patients and other cardiovascular conditions. I am grateful that our new investors have the vision to see 'where the puck is going' in this rapidly emerging field." The MOCA II IDE trial is designed to confirm the CoFl system’s accuracy in diagnosing MVO in high-risk heart attack patients. Led by Principal Investigator Dr. Tim Henry of The Christ Hospital in Cincinnati, Ohio, the trial will recruit several hundred patients undergoing stent implantation due to ST-Elevation Myocardial Infarction (STEMI) and will compare CoFl's proprietary dynamic diagnostic measurement of MVO to post-procedure Contrast Enhanced Cardiac Magnetic Resonance Imaging (CMRI), the current gold standard for detecting MVO. The MOCA II trial leverages the learnings from the company’s First-In-Human MOCA I trial conducted in Switzerland, Latvia and the UK. "There is increasing awareness of the impact of MVO on patient outcomes following coronary revascularization. CorFlow has the potential to be the next significant breakthrough in treating coronary artery disease, and Broadview is delighted to be supporting this impressive team and technology,” states David Prim of Broadview Ventures. "CorFlow's breakthrough technology has been designed by clinicians for clinicians and we are excited to support CorFlow's mission to generate robust clinical data in order to get this much needed therapy to the patient as quickly as possible." adds Barbara Castellano of Panakes Partners. "We also are committed to supporting the emerging field of microvascular disease in general, and this oversubscribed funding round gives us options to apply the technology in new ways, and in new geographies, where patients can benefit.” The funding will also support a novel adaptive platform therapy trial in Europe evaluating whether localized delivery of therapeutics to the microvasculature immediately following stent implantation can improve outcomes in patients diagnosed with MVO. Led by Dr. Giovanni Luigi De Maria (Oxford University Hospitals Trust, UK) and Professor Colin Berry (University of Glasgow and NHS Golden Jubilee National Hospital, UK), this European RCT will assess the effects of several therapeutic agents with both clinical and imaging measures up to six months. "The improvement in outcomes for heart attack patients has stagnated over many years now and we believe that real-time diagnosis and targeted therapy for MVO has the potential to save the lives of countless patients in the future." Comments Frederik Groenewegen of 415 Capital. "We have long been believers in the CorFlow technology and team, and with the support of this first-class investor syndicate we now have the opportunity to collect the clinical data required to establish a new standard of heart attack care." About CorFlow Therapeutics: Headquartered in Baar, Switzerland, with offices in Italy, and founded in 2016 by Dr. Rob Schwartz, Dr. Martin Rothman and Jon Hoem. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart. About Microvascular Obstruction (MVO): Often described as the "last frontier" in the treatment of acute heart attacks, MVO is characterized by blockages in the microvascular coronary arteries, which vary in size down to the circumference of a human hair. Previous research has identified that MVO is one of the most powerful prognostic indicators for future adverse outcomes - for every 1% increase in MVO, there’s a corresponding 14% increase in one-year mortality risk and 8% increase in hospitalization due to heart failure.